Objective: Elevated serum phosphate levels have been associated with increased risks of cardiovascular events and death in several patient populations. The effects of serum phosphate on outcomes in patients with critical limb ischemia (CLI) have not been evaluated. In this study, we assessed the effect of abnormal phosphate levels on mortality and major limb events after surgical intervention for CLI.
Patients undergoing intervention for critical limb ischemia (CLI) are at increased risk of cardiovascular events partly because of the high incidence of associated cardiovascular risk factors. 1, 2 Associations between ambulatory status, cardiac and renal disease, and amputation-free survival have been identified previously in retrospective studies. 3, 4 Despite this, our ability to determine which patients are at increased risk for early and delayed limb and cardiovascular events as well as death remains challenging. Elevated serum phosphate levels have been associated with increased morbidity and mortality in patients with coronary disease, chronic kidney disease, and within the general population. [5] [6] [7] [8] Among patients with a prior myocardial infarction, increased levels are associated with adverse events, including new heart failure, myocardial infarction, and death. 6 Similarly, studies of the The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
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Copyright Despite growing evidence of the adverse effects associated with hyperphosphatemia, the effect of abnormal phosphate levels on patients undergoing vascular interventions have not been previously studied. We therefore sought to evaluate the effect of abnormal postoperative phosphate levels on perioperative outcomes and long-term survival in patients undergoing intervention for CLI.
METHODS
The Institutional Review Board of Beth Israel Deaconess Medical Center approved this study and waived the need for informed consent owing to the retrospective study design.
Patients. All patients undergoing a first-time endovascular or open intervention for CLI, defined as rest pain or  tissue loss, at a single institution between 2005 and 2014 were identified using operative notes and billing data. Electronic medical records were reviewed to confirm the procedures performed. The analysis excluded patients who had undergone previous intervention for peripheral artery disease, those without a diagnosis of CLI, and those without documented postoperative phosphate levels.
Phosphate measurement. Phosphate levels were obtained as part of routine care on admitted postoperative vascular patients because they are included in the basic metabolic panel. Preoperative values were not used for analysis because of missing data (20%). Phosphate and calcium measurements obtained during the 30-day postoperative period were recorded, and a mean serum phosphate level was calculated from the first three phosphate levels collected for each patient. Phosphate levels were normally distributed, and therefore, mean values were used. Phosphate levels were stratified as low (<2.5 mg/dL), normal (2.5-4.5 mg/dL), and high (>4.5 mg/dL) as suggested by United States Food and Drug Administration guidelines and prior studies on serum phosphate. [9] [10] [11] In addition, these values are similar to the National Kidney Foundation's target serum phosphate levels for patients with chronic kidney disease of 2.7 to 4.6 mg/dL.
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Variable definitions. Restenosis was defined as a peak systolic velocity ratio >3.5 in surveillance postprocedural ultrasound imaging or documentation in physician progress notes. Physician progress notes were included in an effort to include patients whose follow-up imaging occurred at another institution. Reintervention was defined as ipsilateral bypass or angioplasty after the initial procedure. Major amputation was defined as any ipsilateral amputation above the ankle. Mortality data were obtained from the Social Security Death Index. Data on wound infections were obtained from hospital discharge summaries and follow up clinic physician notes. A hypercoagulable state was defined as current cancer or documented coagulation disorder. The Society for Vascular Surgery's Lower Extremity Threatened Limb Classification System (Wound, Ischemia, and foot Infection [WIfI] ) was used to compare disease extent in each patient's treated limb. 13 Lesion anatomy was defined according to the modified TransAtlantic Inter-Society Consensus (TASC) classification described by Dormandy and Rutherford. 14 Standard follow-up included duplex imaging at intervals of 3 to 4 months for the first year after the intervention.
Statistics. Patient demographics, comorbid conditions, and operative details were compared across the three phosphate groups. Missing data were encountered in <3% of all patients for most variables studied. Only wound infection (13% missing) and TASC classification (11% missing) exceeded the 3% threshold.
Statistical analyses were performed using Stata 12.0 software (StataCorp LP, College Station, Tex). The c 2 statistic was used for comparisons of categoric variables. Normality of distribution was assessed, and continuous variables were compared using the Student t-test or Kruskal-Wallis testing as appropriate. Kaplan-Meier analysis was used to evaluate trends in mortality and amputation over time. Purposeful selection was used to identify covariates for inclusion in our multivariable model, which includes variables identified on univariate analysis with P < .1 for each end point of interest and clinically relevant factors shown to be predictive of adverse events in previous studies. 15 Logistic regression and Cox modeling were used for multivariable analysis. For adjusted time-to-event analysis we used Cox proportional hazards models after visual inspection of the log-log plot to make sure the baseline hazards assumption held for each adverse event studied in this way. The Hosmer-Lemeshow test was used to confirm the goodness of fit for each multivariable model, and normal phosphate levels were used as the referent group. A P value of <.05 was considered significant.
RESULTS
Baseline characteristics. From 1052 patients who underwent a first-time intervention for CLI, postoperative serum phosphate levels were available for 941 (89%), including 42 (5%) with low, 768 (82%) with normal, and 131 (14%) with high phosphate levels. Significant differences were found in mean age (low: 70, normal: 72, high: 66 years; P < .01) diabetes (low: 66%, normal: 74%, high: 85%; P ¼ .01), congestive heart failure (low: 30%, normal: 30%, high: 42%; P ¼ .02), and dialysis (low: 28%, normal: 15%, high: 55%; P < .01). The proportion treated with bypass also varied (low: 45%, normal: 56%, high: 42%; P ¼ .01). However, neither mean WIfI score nor TASC classification were different among the three phosphate level groups (Table I) . Median follow-up time (26 months) was similar among the groups.
Outcomes. Overall mortality differed significantly among the three groups in the Kaplan-Meier analysis, with high phosphate patients showing significantly worse 1-year survival (low: 19%, normal: 17%, high: 33%; P < .01). Patients with high postoperative phosphate levels also had significantly worse amputation-free survival (P < .01; Fig 1) . Major amputation (low: 12%, normal: 12%, high: 15%) and restenosis (low: 21%, normal: 24%, high: 28%) tended toward worse outcomes among patients with elevated phosphate levels but did not reach statistical significance. In addition, no differences were found in 30-day mortality, major adverse limb events, or wound infection rates among the groups (Table II) .
Multivariable analysis was then used to account for demographics, comorbid conditions, and the index operation. After multivariable analysis, amputation-free survival (hazard ratio [HR], 1.5; 95% confidence interval [CI], 1.2-1.9) and overall mortality (HR, 1.7; 95% CI, 1.3-2.2) were significantly worse among patients with elevated compared with normal phosphate levels (Table III) . A subgroup analysis performed to assess dialysis and nondialysis patients separately found patients with elevated serum phosphate levels had a significantly higher risk of death in each group (dialysis: HR, 1.8 95% CI 1.2-2.6; nondialysis: HR, 1.5; 95% CI, 1.04-2.10). Finally, to confirm that these findings were not the result of differences in renal function, each patient's glomerular filtration rate was included in the multivariable model. High postoperative phosphate levels, however, maintained their association with increased mortality (HR, 1.4; 95% CI, 1.01-2.03). No differences were found in outcomes between patients with normal and low phosphate levels (Table IV) .
DISCUSSION
In this study, we found that patients with elevated postoperative serum phosphate levels undergoing first-time intervention for CLI had increased mortality and decreased amputation-free survival after we adjusted for relevant comorbidities. Outcomes in patients with low compared with normal phosphate levels did not differ. Patients with high phosphate levels were more likely to have end-stage renal disease and diabetes but tended to be younger than those with normal or low levels. Univariate analysis did not identify differences among the three groups in major adverse limb events, including reintervention, restenosis, major amputation, and wound infection.
Our analysis used the average postprocedural phosphate level that was available for 89% of our total CLI population. We also used preoperative and maximum phosphate levels in the analysis but found similar effects on all listed outcomes, including survival, amputationfree survival, and major adverse limb events. Our time-to-event analysis, adjusted for all relevant risk factors, including dialysis, congestive heart failure, diabetes, and tobacco use, demonstrated a persistent and durable effect of postoperative phosphate levels on survival.
The results of this study support findings from prior investigations of nonsurgical patients with chronic kidney disease, cardiac disease, and within the general population. [5] [6] [7] The relationship between serum phosphate levels and death is not well understood. Increasing evidence, however, supports a role for phosphate in the pathogenesis of medial and intimal calcification. 16 Cox analysis adjusted for age, dialysis, congestive heart failure, chronic obstructive pulmonary disease, diabetes, and index procedure. c Cox analysis adjusted for age, dialysis, congestive heart failure, chronic obstructive pulmonary disease, diabetes, index procedure, and smoking. levels were strongly associated with noncompressible vessels and increased ankle-brachial index after adjusting for renal function and cardiovascular risk factors. The authors suggest that increased cardiovascular events might be explained by increased arterial stiffness related to medial artery calcification. 18 In the Coronary Artery Risk Development in Young Adults (CARDIA) study, Foley et al 7 also demonstrated that elevated serum phosphate levels were associated with coronary artery calcification in patients without a history of renal dysfunction. In patients with peripheral arterial disease, calcification has been associated with increased rates of amputation and death, further supporting the hypothesis that decreased amputation-free survival among patients with elevated phosphate may be related to increased arterial calcification. 19, 20 The increased mortality in patients with hyperphosphatemia has been demonstrated in multiple studies of patients with end-stage renal disease. 21, 22 Despite these findings, it remains possible that increased serum phosphate levels may reflect advanced coronary or renal disease. To further evaluate the effect of these factors on mortality, we performed a stratified analysis of dialysis and nondialysis patients, adjusting for cardiac risk factors. This revealed a similar effect on mortality for both populations, suggesting that elevated serum phosphate levels have a detrimental effect on survival, independent of renal and cardiac disease. Similarly, when the glomerular filtration rate was included in the model, the effect on mortality remained. These findings support previous studies that demonstrated similar effects among patients without renal dysfunction. Dhingra et al 8 described
the effect of hyperphosphatemia on cardiovascular events in the large prospective Framingham Offspring Study and found a significant association between elevated serum phosphate levels and increased risk of cardiovascular disease among individuals free of chronic kidney or cardiovascular disease in the community. The role of serum phosphate levels in heterotopic calcification has only recently been explored. Arterial calcification is a complex process promoted through an imbalance between endogenous stimulators and inhibitors. 17 Vascular smooth muscle cells respond to increased phosphate levels by undergoing osteochondrogenic differentiation with subsequent mineralization of the extracellular matrix. This process can be amplified by cytokines that increase the expression of sodium-dependent phosphate cotransporters in the smooth muscle cells, thus increasing their susceptibility to calcification. 17 The presence of coronary and tibial artery calcification is associated with increased cardiovascular events, lower extremity amputation, and death. 20, [23] [24] [25] The primary treatment approaches to hyperphosphatemia are currently dietary phosphate restriction, oral phosphate binders, and vitamin D (1,25) supplementation. 26 Historically, treatment was limited to patients on hemodialysis; however, recent guidelines now also recommend treatment for patients with chronic kidney disease owing to the associated adverse outcomes of untreated hyperphosphatemia. 12 Clinical trials have shown phosphate binders are successful in reducing serum phosphate levels as well as secondary hyperparathyroid hormone and fibroblast growth factor 23, which occur in conjunction with hyperphosphatemia. 26 The efficacy of phosphate reduction on improving overall mortality, however, is unknown, and large clinical trials have yet to evaluate the effect of serum phosphate reduction on mortality. 12, 27, 28 Decreased amputation-free survival associated with hyperphosphatemia may have important clinical implications for the treatment of patients with CLI. Our results suggest that perioperative serum phosphate levels provide valuable prognostic information regarding patient mortality and amputation-free survival. This study also highlights the need to identify phosphate management strategies in patients with CLI even when concurrent renal dysfunction is not present. Although hyperphosphatemia is commonly treated among patients on hemodialysis, current management guidelines now emphasize the importance of maintaining normal phosphate levels in those with earlier states of renal disease. 12 Measurement of serum phosphate in the perioperative period may thus provide an opportunity to identify those patients at elevated risk. Finally, our data provide a clinical rational for further investigations on the role of phosphate in long-term outcomes of CLI patients.
Our study has several limitations. First, it is a retrospective review of patients at a single institution and reinterventions or amputation may be underestimated due to uncaptured events. This study also had a small sample size of patients with low phosphate, and it is possible that differences in outcomes between low and normal phosphate levels may exist but were not identified due to inadequate power. Finally, laboratory values in the 30-day postoperative period may not represent a patient's normal baseline, and owing to missing data, we were unable to assess preoperative phosphate levels for our analysis. However, when we ran our analysis using patients' preoperative phosphate levels (n ¼ 756), the statistical association of elevated phosphate levels with worse amputation-free survival remained. Nonetheless, our data suggest that abnormal phosphate levels during the perioperative period identify a patient population at increased risk of death.
CONCLUSIONS
Elevated serum phosphate levels are associated with increased mortality and decreased amputation-free survival in patients with CLI. Future research focusing on the effects of serum phosphate in patients with CLI is warranted. 
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